# Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus

> **NCT00085969** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 99 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Placebo 0.04 mL twice daily
- **DRUG:** Placebo 0.04 mL once daily
- **DRUG:** Placebo 0.08 mL once daily
- **DRUG:** B - Exenatide 10 mcg twice daily
- **DRUG:** C - Exenatide 10 mcg once daily
- **DRUG:** Exenatide 20 mcg once daily

## Key facts

- **NCT ID:** NCT00085969
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2004-01
- **Final completion:** 2004-01
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2015-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00085969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00085969, "Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00085969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*